Introduction {#sec1_1}
============

Guillain-Barré syndrome (GBS) is a peripheral nerve disorder with acute weakness of the distal limbs and absent tendon reflexes \[[@B1]\]. Fisher syndrome (FS) is a subtype of GBS characterized by diplopia, ataxia, and the loss of deep-tendon reflexes \[[@B2]\]. The clinical course is generally monophasic, and the recurrence of both GBS and FS is rare. Although human leukocyte antigen (HLA) might be associated with recurrent GBS or FS, the characteristics of patients with such recurrence have not been fully elucidated \[[@B3]\]. We describe the cases of 2 patients with recurrent GBS and FS who were subsequently diagnosed as aplastic anemia.

Case Reports {#sec1_2}
============

Case 1 {#sec2_1}
------

A 66-year-old man with aplastic anemia was admitted with a gait disturbance due to ataxia and a sensory disturbance of the distal limbs 3 days after an upper respiratory tract infection. He had a history of diplopia and ataxia after similar infections at the ages of 38 and 56 years, respectively, and was diagnosed with FS at the time of the second infection. He had been diagnosed with aplastic anemia accompanied by paroxysmal nocturnal hemoglobinuria

(AA-PNH) by a bone-marrow biopsy 10 months before admission. Immunosuppressive therapy with anti-thymoglobulin and cyclosporine was performed for aplastic anemia, but the therapeutic effect was insufficient. The aplastic anemia was in remission under treatment with eltrombopag.

A neurological examination upon admission revealed limb ataxia, a sensory disturbance of the distal limbs, absent deep-tendon reflexes and decreased grip forces of 25 and 23 kg in the right and left hands, respectively. A complete blood count, biochemical and coagulation findings were normal. Cell counts were normal (7/3) and protein in cerebrospinal fluid samples was elevated (44 mg/dL). Nerve conduction findings were unremarkable in the right medial, ulnar, and tibial motor nerves. We diagnosed recurrent FS and treated him with intravenous immunoglobulin (0.5 g/kg). His neurological symptoms gradually improved, and he was able to walk independently 7 days after admission and was discharged 11 days from admission. His blood examination revealed positive IgG-type anti-ganglioside (GQ1b) antibody and HLA-DR15, negative IgM type GQ1b antibody.

Case 2 {#sec2_2}
------

A 66-year-old woman had been diagnosed with aplastic anemia from a PNH clone 1 year before and treated with cyclosporin, and was currently in remission. She had a history of distal limb weakness with loss of deep-tendon reflexes at 7 days after upper respiratory tract infections at the ages of 39 and 60 years. A nerve conduction study during the second infection showed low amplitude; however, decreasing conduction speed or conduction block which suggested chronic inflammatory demyelinating polyneuropathy were not found in the right median motor nerve (NCV, 51.3 m/s; wrist, 4.150 mV; elbow, 1.570 mV). She was also positive for IgG type GM-1 and GQ1b antibodies. She was diagnosed with recurrent GBS and treated with intravenous immunoglobulin (0.5 g/kg). Her neurological deficits disappeared, but she remained positive for HLA-DR15.

Discussion {#sec1_3}
==========

These patients had a history of at least two recurrences of GBS or FS and were subsequently diagnosed with aplastic anemia. The reported rates of GBS occurrence in Japan are 0.62--2.66 per 100,000 and that of FS was almost one-third of GBS \[[@B4]\], and those of recurrence are 2--5 and 14%, respectively \[[@B2], [@B5]\]. Thus, GBS and FS are known to recur, but the frequency was admittedly rare.

The characteristics of recurrence have not been fully elucidated. Genetic factors might be involved in the development of GBS or FS. A relationship between HLA-DR2 and GBS has been suspected, but this remains debatable \[[@B6], [@B7]\]. On the contrary, Chida et al. \[[@B3]\] found that HLA-DR2 positivity might be associated with the occurrence of FS. The patients in their study were positive for HLA-DR15 (a subtype of HLA-DR2); thus HLA-DR15 might be involved in recurrent GBS or FS \[[@B8]\]. One notion is that GBS develops when peripheral nerves are damaged by cellular immunity. Because HLA-DR15 tends to induce Th0 cell differentiation into Th1 or Th17 cells that are associated with cellular immunity, patients who are HLA-DR15 positive might be more susceptible to developing GBS or FS \[[@B9], [@B10], [@B11], [@B12]\]. However, as there are no studies which examined the correlation with HLA-DR15 and GBS or FS, further examination will be needed in the future.

Our patients were treated with cyclophosphamide or cyclosporin for AA-PNH. The mechanism of aplastic anemia is not fully understood: AA-PNH might be caused via a mechanism in which killer T cells attack blood cells under a PNH clone with but not without a GPI-anchored protein \[[@B13], [@B14]\]. Aplastic anemia is caused by autoimmune attack to hematopoietic stem cells, resulting in decrease in the number of stem cells. PNH clones derived from stem cells deficient in GPI-anchored proteins are present only below normal measurement sensitivity. However, in cases of aplastic anemia, since PNH clones remain resistant to attack by self-reactive lymphocytes, relatively expanded compared to normal stem cells, PNH clones are believed to be detectable. Because positive HLA-DR15 tends to suppress the activity of regulatory T cell that control the activity of killer T cells, hyperactive killer T cells might contribute to the onset of aplastic anemia \[[@B15], [@B16]\]. Kaya et al. \[[@B17]\]described a patient with aplastic anemia who developed GBS because T cell-controlled B-cell activation had been suppressed by the administration of anti-lymphocytes. In the case, treatment by intravenous immunoglobulin was effective for both GBS and aplastic anemia. Intravenous immunoglobulin has the effect of increasing regulatory T cell and suppression of tumor necrosis factor-α and interferon-γ \[[@B18]\]. This supported T cell was associated with both GBS and aplastic anemia. In addition, anchor protein might be associated with both aplastic anemia and GBS, as gangliosides that are targets in GBS are glycosphingolipids linked to an anchor protein \[[@B19]\].

We described 2 patients with recurrence of GBS and FS who were subsequently diagnosed with aplastic anemia. The recurrence of these pathologies and their association with HLA-DR15 require further investigation.
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